|
1
|
Gebe JA, Kiener PA, Ring HZ, Li X, Francke
U and Aruffo A: Molecular cloning, mapping to human chromosome 1
q21–q23, and cell binding characteristics of Spalpha, a new member
of the scavenger receptor cysteine-rich (SRCR) family of proteins.
J Biol Chem. 272:6151–6158. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sarrias MR, Roselló S, Sánchez-Barbero F,
Sierra JM, Vila J, Yélamos J, Vives J, Casals C and Lozano F: A
role for human Spα as a pattern recognition receptor. J Biol Chem.
280:35391–35398. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Miyazaki T, Hirokami Y, Matsuhashi N,
Takatsuka H and Naito M: Increased susceptibility of thymocytes to
apoptosis in mice lacking AIM, a novel murine macrophage-derived
soluble factor belonging to the scavenger receptor cysteine-rich
domain superfamily. J Exp Med. 189:413–422. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gebe JA, Llewellyn M, Hoggatt H and Aruffo
A: Molecular cloning, genomic organization and cell-binding
characteristics of mouse Spalpha. Immunology. 99:78–86. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kuwata K, Watanabe H, Jiang SY, Yamamoto
T, Tomiyama-Miyaji C, Abo T, Miyazaki T and Naito M: AIM inhibits
apoptosis of T cells and NKT cells in Corynebacterium-induced
granuloma formation in mice. Am J Pathol. 162:837–847. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Haruta I, Kato Y, Hashimoto E, Minjares C,
Kennedy S, Uto H, Yamauchi K, Kobayashi M, Yusa S, Müller U, et al:
Association of AIM, a novel apoptosis inhibitory factor, with
hepatitis via supporting macrophage survival and enhancing
phagocytotic function of macrophages. J Biol Chem. 276:22910–22914.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bensinger SJ and Tontonoz P: Integration
of metabolism and inflammation by lipid-activated nuclear
receptors. Nature. 454:470–477. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Joseph SB, Bradley MN, Castrillo A, Bruhn
KW, Mak PA, Pei L, Hogenesch J, O'Connell RM, Cheng G, Saez E, et
al: LXR-dependent gene expression is important for macrophage
survival and the innate immune response. Cell. 119:299–309. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Valledor AF, Hsu LC, Ogawa S,
Sawka-Verhelle D, Karin M and Glass CK: Activation of liver X
receptors and retinoid X receptors prevents bacterial-induced
macrophage apoptosis. Proc Natl Acad Sci USA. 101:17813–17818.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arai S, Shelton JM, Chen M, Bradley MN,
Castrillo A, Bookout AL, Mak PA, Edwards PA, Mangelsdorf DJ,
Tontonoz P, et al: A role for the apoptosis inhibitory factor
AIM/Spalpha/Api6 in atherosclerosis development. Cell Metab.
1:201–213. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Amézaga N, Sanjurjo L, Julve J, Aran G,
Pérez-Cabezas B, Bastos-Amador P, Armengol C, Vilella R, Escolà-Gil
JC, Blanco-Vaca F, et al: Human scavenger protein AIM increases
foam cell formation and CD36-mediated oxLDL uptake. J Leukoc Biol.
95:509–520. 2014. View Article : Google Scholar
|
|
12
|
Martinez VG, Escoda-Ferran C, Tadeu Simões
I, Arai S, Orta Mascaró M, Carreras E, Martínez-Florensa M, Yelamos
J, Miyazaki T and Lozano F: The macrophage soluble receptor
AIM/Api6/CD5L displays a broad pathogen recognition spectrum and is
involved in early response to microbial aggression. Cell Mol
Immunol. 11:343–354. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Li Y, Qu P, Wu L, Li B, Du H and Yan C:
Api6/AIM/Spα/CD5L overexpression in alveolar type II epithelial
cells induces spontaneous lung adenocarcinoma. Cancer Res.
71:5488–5499. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Qu P, Du H, Li Y and Yan C:
Myeloid-specific expression of Api6/AIM/Sp alpha induces systemic
inflammation and adenocarcinoma in the lung. J Immunol.
182:1648–1659. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kurokawa J, Arai S, Nakashima K, Nagano H,
Nishijima A, Miyata K, Ose R, Mori M, Kubota N, Kadowaki T, et al:
Macrophage-derived AIM is endocytosed into adipocytes and decreases
lipid droplets via inhibition of fatty acid synthase activity. Cell
Metab. 11:479–492. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hwa V, Oh Y and Rosenfeld RG: The
insulin-like growth factor-binding protein (IGFBP) superfamily.
Endocr Rev. 20:761–787. 1999.PubMed/NCBI
|
|
17
|
Firth SM and Baxter RC: Cellular actions
of the insulin-like growth factor binding proteins. Endocr Rev.
23:824–854. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Clemmons DR: Use of mutagenesis to probe
IGF-binding protein structure/function relationships. Endocr Rev.
22:800–817. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bach LA, Headey SJ and Norton RS:
IGF-binding proteins - the pieces are falling into place. Trends
Endocrinol Metab. 16:228–234. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zimmermann EM, Li L, Hoyt EC, Pucilowska
JB, Lichtman S and Lund PK: Cell-specific localization of
insulin-like growth factor binding protein mRNAs in rat liver. Am J
Physiol Gastrointest Liver Physiol. 278:G447–G457. 2000.PubMed/NCBI
|
|
21
|
Kuemmerle JF: Insulin-like growth factors
in the gastrointestinal tract and liver. Endocrinol Metab Clin
North Am. 41:409–423. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bunn RC and Fowlkes JL: Insulin-like
growth factor binding protein proteolysis. Trends Endocrinol Metab.
14:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sitar T, Popowicz GM, Siwanowicz I, Huber
R and Holak TA: Structural basis for the inhibition of insulin-like
growth factors by insulin-like growth factor-binding proteins. Proc
Natl Acad Sci USA. 103:13028–13033. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mohan S and Baylink DJ: IGF-binding
proteins are multifunctional and act via IGF-dependent and
-independent mechanisms. J Endocrinol. 175:19–31. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Moreno MJ, Ball M, Rukhlova M, Slinn J,
L'abbe D, Iqbal U, Monette R, Hagedorn M, O'Connor-McCourt MD,
Durocher Y, et al: IGFBP-4 anti-angiogenic and anti-tumorigenic
effects are associated with anti-cathepsin B activity. Neoplasia.
15:554–567. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Ryan AJ, Napoletano S, Fitzpatrick PA,
Currid CA, O'Sullivan NC and Harmey JH: Expression of a
protease-resistant insulin-like growth factor-binding protein-4
inhibits tumour growth in a murine model of breast cancer. Br J
Cancer. 101:278–286. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sueoka N, Lee HY, Wiehle S, Cristiano RJ,
Fang B, Ji L, Roth JA, Hong WK, Cohen P and Kurie JM: Insulin-like
growth factor binding protein-6 activates programmed cell death in
non-small cell lung cancer cells. Oncogene. 19:4432–4436. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Perks CM, Newcomb PV, Norman MR and Holly
JM: Effect of insulin-like growth factor binding protein-1 on
integrin signalling and the induction of apoptosis in human breast
cancer cells. J Mol Endocrinol. 22:141–150. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Durai R, Davies M, Yang W, Yang SY,
Seifalian A, Goldspink G and Winslet M: Biology of insulin-like
growth factor binding protein-4 and its role in cancer (Review).
Int J Oncol. 28:1317–1325. 2006.PubMed/NCBI
|
|
30
|
Arai S and Miyazaki T: Impacts of the
apoptosis inhibitor of macrophage (AIM) on obesity-associated
inflammatory diseases. Semin Immunopathol. 36:3–12. 2014.
View Article : Google Scholar :
|
|
31
|
Sanjurjo L, Amézaga N, Vilaplana C,
Cáceres N, Marzo E, Valeri M, Cardona PJ and Sarrias MR: The
scavenger protein apoptosis inhibitor of macrophages (AIM)
potentiates the antimicrobial response against Mycobacterium
tuberculosis by enhancing autophagy. PLoS One. 8:e796702013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kai T, Yamazaki T, Arai S and Miyazaki T:
Stabilization and augmentation of circulating AIM in mice by
synthesized IgM-Fc. PLoS One. 9:e970372014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Daza DO, Sundström G, Bergqvist CA, Duan C
and Larhammar D: Evolution of the insulin-like growth factor
binding protein (IGFBP) family. Endocrinology. 152:2278–2289. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Galea CA, Mobli M, McNeil KA, Mulhern TD,
Wallace JC, King GF, Forbes BE and Norton RS: Insulin-like growth
factor binding protein-2: NMR analysis and structural
characterization of the N-terminal domain. Biochimie. 94:608–616.
2012. View Article : Google Scholar
|
|
35
|
Forbes BE, McCarthy P and Norton RS:
Insulin-like growth factor binding proteins: A structural
perspective. Front Endocrinol (Lausanne). 3:382012.
|
|
36
|
Damon SE, Maddison L, Ware JL and Plymate
SR: Overexpression of an inhibitory insulin-like growth factor
binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor
formation. Endocrinology. 139:3456–3464. 1998.PubMed/NCBI
|
|
37
|
Zhou R, Flaswinkel H, Schneider MR, Lahm
H, Hoeflich A, Wanke R and Wolf E: Insulin-like growth
factor-binding protein-4 inhibits growth of the thymus in
transgenic mice. J Mol Endocrinol. 32:349–364. 2004. View Article : Google Scholar : PubMed/NCBI
|
